EA202192107A1 - Тритерпеноидные фунгициды для лечения грибковых костно-суставных инфекций - Google Patents

Тритерпеноидные фунгициды для лечения грибковых костно-суставных инфекций

Info

Publication number
EA202192107A1
EA202192107A1 EA202192107A EA202192107A EA202192107A1 EA 202192107 A1 EA202192107 A1 EA 202192107A1 EA 202192107 A EA202192107 A EA 202192107A EA 202192107 A EA202192107 A EA 202192107A EA 202192107 A1 EA202192107 A1 EA 202192107A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
triterpenoid
fungal
bone
fungicides
Prior art date
Application number
EA202192107A
Other languages
English (en)
Russian (ru)
Inventor
Давид А. Ангуло Гонсалес
Original Assignee
Сайнексис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайнексис, Инк. filed Critical Сайнексис, Инк.
Publication of EA202192107A1 publication Critical patent/EA202192107A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
EA202192107A 2019-01-30 2020-01-30 Тритерпеноидные фунгициды для лечения грибковых костно-суставных инфекций EA202192107A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962798743P 2019-01-30 2019-01-30
PCT/US2020/015948 WO2020160316A1 (en) 2019-01-30 2020-01-30 Triterpenoid antifungals for the treatment of fungal osteo-articular infections

Publications (1)

Publication Number Publication Date
EA202192107A1 true EA202192107A1 (ru) 2021-10-21

Family

ID=69740705

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192107A EA202192107A1 (ru) 2019-01-30 2020-01-30 Тритерпеноидные фунгициды для лечения грибковых костно-суставных инфекций

Country Status (7)

Country Link
US (2) US20220117948A1 (cg-RX-API-DMAC7.html)
EP (1) EP3917534B1 (cg-RX-API-DMAC7.html)
JP (1) JP7562542B2 (cg-RX-API-DMAC7.html)
CN (1) CN113498343A (cg-RX-API-DMAC7.html)
EA (1) EA202192107A1 (cg-RX-API-DMAC7.html)
MA (1) MA54866A (cg-RX-API-DMAC7.html)
WO (1) WO2020160316A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020276595B2 (en) * 2019-05-16 2025-12-04 Scynexis, Inc. Antifungal Agents for Candida Auris Decolonization

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
ES2402659T3 (es) 2006-04-03 2013-05-07 Merck Sharp & Dohme Corp. Derivados de enfumafungina como agentes antifúngicos
WO2010019204A1 (en) * 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
BRPI0912074B1 (pt) * 2008-08-12 2021-08-03 Merck Sharp & Dohme Corp Composto e composição farmacêutica
US20210002346A1 (en) * 2016-11-29 2021-01-07 Cidara Therapeutics, Inc Methods for preventing fungal infections

Also Published As

Publication number Publication date
EP3917534B1 (en) 2024-07-03
US20220117948A1 (en) 2022-04-21
CN113498343A (zh) 2021-10-12
EP3917534A1 (en) 2021-12-08
MA54866A (fr) 2022-05-04
WO2020160316A1 (en) 2020-08-06
US20250248983A1 (en) 2025-08-07
JP2022519500A (ja) 2022-03-24
JP7562542B2 (ja) 2024-10-07

Similar Documents

Publication Publication Date Title
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
MY196599A (en) Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
PL417066A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
MX2011012143A (es) Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas.
ZA202300259B (en) Compound for the treatment of coronaviral infections
CR20210480A (es) Formulaciones farmacéuticas
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
SG11201908234WA (en) Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
PE20200600A1 (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc
MX418886B (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo
MX2017016774A (es) Agente terapeutico para la fibrosis.
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
MY191183A (en) (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
EA201990766A1 (ru) Индазольные соединения для применения при повреждениях сухожилий и/или связок
MX2021002590A (es) Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
AR121477A1 (es) Compuestos y métodos para el tratamiento de infecciones fúngicas
EA201992413A1 (ru) Противогрибковые средства, используемые в комбинации
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
MX2022006180A (es) Derivados macrociclicos de sulfonilo como inhibidores de mcl-1.
EA202191415A1 (ru) Комбинированная терапия, включающая ингибитор krasg12c и одно или несколько дополнительных фармацевтически активных средств, для лечения видов рака
EA201891739A1 (ru) ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА (NASH)